{"id":"ad1d3dc7-349b-5555-8941-6c2bb6872c93","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-nr-vascular-bound","predicate":"does_not_establish_corrected_reduction_in","statement":"The observed decrease in aortic pulse-wave velocity did not reach statistical significance after multiple-comparison correction; carotid compliance and brachial flow-mediated dilation showed no effect.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"d9ca2b02-2ebd-5076-88bf-e94c7884cc3f","mechanism_event_label":"A higher blood NAD level was clearer than the exploratory vascular benefit in this trial.","subject":{"id":"7bb72d0e-e20d-51bc-b88b-7ff29dc2ad4a","slug":"nicotinamide-riboside","display_name":"Nicotinamide riboside","entity_type_key":"small_molecule"},"object":{"id":"8ad754e3-5604-5baa-9cff-2e9e14384be5","slug":"aortic-pulse-wave-velocity","display_name":"Aortic pulse-wave velocity","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"d9ca2b02-2ebd-5076-88bf-e94c7884cc3f","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-nr-vascular-bound-event","event_type":"observed_intervention","label":"A higher blood NAD level was clearer than the exploratory vascular benefit in this trial.","description":"The observed decrease in aortic pulse-wave velocity did not reach statistical significance after multiple-comparison correction; carotid compliance and brachial flow-mediated dilation showed no effect.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"7bb72d0e-e20d-51bc-b88b-7ff29dc2ad4a","slug":"nicotinamide-riboside","display_name":"Nicotinamide riboside","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8ad754e3-5604-5baa-9cff-2e9e14384be5","slug":"aortic-pulse-wave-velocity","display_name":"Aortic pulse-wave velocity","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"Niacin precursor form and the measured endpoint are separate graph entities.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-clinical-sources/martens2018.txt\", \"locator\": \"Primary full report; exact character range, zero-based and end-exclusive\", \"file_sha256\": \"6743a5d9ad919ee67fb74af7f173b24bda66943d9c8878d6bc3bb72c80b2c37e\", \"start_char\": 21021, \"end_char\": 21948, \"text_sha256\": \"f7cee4adec07fb2c817d28092fb58a099173a569a7f20c6421687b8d995d31d2\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind crossover; 30 randomized, 24 healthy adults aged 55–79 completed","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nicotinamide riboside chloride 500 mg twice daily versus placebo, six weeks each","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small short trial, no formal washout, directional tests; secondary endpoints adjusted for multiple comparisons. PBMC NAD is not all-tissue NAD or evidence of lifespan extension.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A higher blood NAD level was clearer than the exploratory vascular benefit in this trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[nia-clin-martens2018] Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. (2018). https://pubmed.ncbi.nlm.nih.gov/29599478/ DOI: 10.1038/s41467-018-03421-7","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Peripheral blood mononuclear cells and vascular physiology","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"09fe7a3e-6880-5093-9f1a-8faf1511776b","evidence_kind":"source_excerpt","locator":"Lines 1473-1485","start_line":1473,"end_line":1485,"excerpt":"### nia-clin-nr-vascular-bound\nThe observed decrease in aortic pulse-wave velocity did not reach statistical significance after multiple-comparison correction; carotid compliance and brachial flow-mediated dilation showed no effect.\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A higher blood NAD level was clearer than the exploratory vascular benefit in this trial.\norganism: Homo sapiens\ntissue_or_cell_type: Peripheral blood mononuclear cells and vascular physiology\nexperimental_model: Randomized double-blind crossover; 30 randomized, 24 healthy adults aged 55–79 completed\nlimitations: Small short trial, no formal washout, directional tests; secondary endpoints adjusted for multiple comparisons. PBMC NAD is not all-tissue NAD or evidence of lifespan extension.\nexposure: Nicotinamide riboside chloride 500 mg twice daily versus placebo, six weeks each\ncross_nutrient: Niacin precursor form and the measured endpoint are separate graph entities.\nevidence_span: {\"source_cache\": \"artifacts/niacin-clinical-sources/martens2018.txt\", \"locator\": \"Primary full report; exact character range, zero-based and end-exclusive\", \"file_sha256\": \"6743a5d9ad919ee67fb74af7f173b24bda66943d9c8878d6bc3bb72c80b2c37e\", \"start_char\": 21021, \"end_char\": 21948, \"text_sha256\": \"f7cee4adec07fb2c817d28092fb58a099173a569a7f20c6421687b8d995d31d2\"}\n[nia-clin-martens2018] Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. (2018). https://pubmed.ncbi.nlm.nih.gov/29599478/ DOI: 10.1038/s41467-018-03421-7","model_system":"Randomized double-blind crossover; 30 randomized, 24 healthy adults aged 55–79 completed","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [nia-clin-martens2018] Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. (2018). https://pubmed.ncbi.nlm.nih.gov/29599478/ DOI: 10.1038/s41467-018-03421-7","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}